Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | STAT1 | P42224 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3102896 | 0.85 | MGAM (0.57) | MGAMRAB9ACFTRCYP1A2MAOB | |
| SCHEMBL29750532 | 0.85 | MGAM (0.57) | MGAMRAB9ACFTRCYP1A2MAOB | |
| SCHEMBL530807 | 0.84 | TRPM5 (0.50) | MGAMRAB9ACFTRCYP1A2NPSR1 | |
| SCHEMBL12505006 | 0.81 | MGAM (0.57) | MGAMRAB9ACFTRNPC1FAAH | |
| SCHEMBL6597946 | 0.80 | CYP1A2 (0.52) | MGAMRAB9ACFTRCYP1A2HPGD | |
| SCHEMBL4069176 | 0.80 | CYP1A2 (0.53) | MGAMRAB9ACFTRCYP1A2NPSR1 | |
| SCHEMBL14075590 | 0.80 | MGAM (0.47) | MGAMRAB9ACFTRCYP1A2NPSR1 | |
| SCHEMBL6239112 | 0.80 | KDM4E (0.55) | MGAMRAB9ANPC1HPGDNFKB1 | |
| SCHEMBL5856432 | 0.79 | CYP1A2 (0.52) | MGAMRAB9ACFTRCYP1A2MAOB | |
| SCHEMBL24487053 | 0.79 | CYP1A2 (0.42) | MGAMRAB9ACFTRCYP1A2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2917214-A1 | SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2015-09-16 | — | — | EP | claimed |
| WO-2014072220-A1 | SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-05-15 | — | — | WO | claimed |
| CN-1780821-A | Heterocyclic kinase inhibitors. | ABBOTT LAB (US) | 2006-05-31 | — | — | CN | claimed |
| EP-2917214-A1 | SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2015-09-16 | — | — | EP | disclosed |
| WO-2014072220-A1 | SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-05-15 | — | — | WO | disclosed |
| WO-2014067985-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM SCIENCE PARK S.P.A. (IT) | 2014-05-08 | — | — | WO | disclosed |
| EP-2597955-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-8431556-B2 | C-21-keto lupane derivatives preparation and use thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-30 | — | — | US | disclosed |
| US-8394828-B2 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | disclosed |
| WO-2012016082-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-02-02 | — | — | WO | disclosed |
| US-20110077228-A1 | NOVEL C-21-KETO LUPANE DERIVATIVES PREPARATION AND USE THEREOF | MOINET CHRISTOPHE | 2011-03-31 | — | — | US | disclosed |
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080027012-A1 | BRIDGED CARBAMATE MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20080027012-A1 | BRIDGED CARBAMATE MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-01-31 | — | — | US | disclosed |
| WO-2008014221-A2 | BRIDGED CARBAMATE MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-7312201-B2 | Tetracyclic bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312201-B2 | Tetracyclic bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2007115278-A2 | 3,6,11-TRICYCLOLIDE | ENANTA PHARMACEUTICALS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| CN-1780821-A | Heterocyclic kinase inhibitors. | ABBOTT LAB (US) | 2006-05-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027012-A1 | BRIDGED CARBAMATE MACROLIDES | HDAC6, SI, HDAC3 | MGAM 128/4885RAB9A 1263/4885CFTR 43/4885 |
| US-20110077228-A1 | NOVEL C-21-KETO LUPANE DERIVATIVES PREPARATION AND USE THEREOF | CYP51A1, CYP17A1, HSD17B7 | MGAM 3226/4885RAB9A 2221/4885CFTR 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.